| Title |
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
|
|---|---|
| Published in |
PLOS ONE, September 2009
|
| DOI | 10.1371/journal.pone.0007258 |
| Pubmed ID | |
| Authors |
Patrice Dubreuil, Sébastien Letard, Marco Ciufolini, Laurent Gros, Martine Humbert, Nathalie Castéran, Laurence Borge, Bérengère Hajem, Anne Lermet, Wolfgang Sippl, Edwige Voisset, Michel Arock, Christian Auclair, Phillip S. Leventhal, Colin D. Mansfield, Alain Moussy, Olivier Hermine |
| Abstract |
The stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of masitinib (AB1010), a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets KIT. |
Mendeley readers
The data shown below were compiled from readership statistics for 251 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 2 | <1% |
| Brazil | 2 | <1% |
| Germany | 1 | <1% |
| Switzerland | 1 | <1% |
| United Kingdom | 1 | <1% |
| Mexico | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 242 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 50 | 20% |
| Student > Ph. D. Student | 35 | 14% |
| Other | 27 | 11% |
| Student > Master | 25 | 10% |
| Student > Bachelor | 23 | 9% |
| Other | 40 | 16% |
| Unknown | 51 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 19% |
| Agricultural and Biological Sciences | 36 | 14% |
| Biochemistry, Genetics and Molecular Biology | 28 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 21 | 8% |
| Chemistry | 20 | 8% |
| Other | 43 | 17% |
| Unknown | 56 | 22% |